Changing paradigm in advanced and metastatic non-small cell lung cancer

Dipesh Uprety; Kaushal Parikh; Anita Sawkar; Anastasios Dimou; Konstantinos Leventakos

doi:10.21037/jtd-20-1472

Changing paradigm in advanced and metastatic non-small cell lung cancer

J Thorac Dis. 2020 Nov;12(11):6992-7001. doi: 10.21037/jtd-20-1472.

Authors

Dipesh Uprety¹, Kaushal Parikh², Anita Sawkar³, Anastasios Dimou¹, Konstantinos Leventakos¹

Affiliations

¹ Department of Oncology, Mayo Clinic, Rochester, MN, USA.
² Department of Oncology, Hackensack University Medical Center, Hackensack, NJ, USA.
³ Department of Internal Medicine, Hackensack University Medical Center, Hackensack, NJ, USA.

Abstract

Lung cancer is the most common cancer worldwide. Approximately 18% of all deaths related to cancer are associated with lung cancer. Management of non-small cell lung cancer (NSCLC) has been changing rapidly in last few years. For patients with unresectable non-metastatic disease, maintenance durvalumab is now given after offering chemo-radiation concurrently based on the result from the PACIFIC trial. Management of metastatic disease greatly depends on the status of sensitizing driver mutation and PD-L1 level of the tumor cells. In this review article, we will summarize the outcome of various clinical trials and will provide the most up-to-date information on the management of patients with advanced and metastatic NSCLC.

Keywords: Advanced; lung cancer; metastatic; non-small cell lung cancer (NSCLC); stage III; stage IV.

Publication types

Review